Physician profile
Steven Frey
NPI 1396943619
$54,558.45
in general payments reported to CMS, 2019-2025
12 companies · $45K in 2025
The $45K reported for 2025 was more than what 94% of Sports Medicine (Orthopaedic Surgery) providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,192 · 2020: $35.83 · 2021: $147 · 2022: $81.94 · 2023: $829 · 2024: $3,263 · 2025: $45K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $44K · Travel and Lodging: $3,973 · Food and Beverage: $1,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $43,975.00 |
| Travel and Lodging | $3,973.42 |
| Food and Beverage | $1,152.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $50,291.68 | 2019-2025 | Arthrex |
| Liberty Surgical INC. | $2,646.97 | 2019 | |
| Eclipse Technology Solutions INC. | $798.18 | 2023-2025 | |
| Stryker Corporation | $442.79 | 2019-2023 | Mako, Insignia, Triathlon |
| Smith+Nephew, INC. | $164.24 | 2025 | Q-Fix |
| Organogenesis INC. | $73.87 | 2021 | |
| Depuy Synthes Sales INC. | $34.99 | 2025 | Orthovisc, Monovisc |
| Vericel Corporation | $30.62 | 2021-2025 | Maci |
| Avanos Medical | $24.93 | 2019 | |
| Novo Nordisk INC | $20.29 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $16.43 | 2024 | Zilretta, Exparel, Iovera |
| Misonix INC | $13.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Frey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.